MUNICH, Germany – Waiv (formerly Owkin Dx) has published the results of a multicentre external validation study of BRCAura in npj Precision Oncology. BRCAura is an AI model that predicts germline BRCA1/2 mutation status from routine H&E-stained breast cancer whole slide images (WSIs). Aigora curated and provided the study’s biopsy validation cohort, one of six external validation cohorts.
Germline BRCA1/2 mutations are among the most actionable findings in hormone receptor-positive, HER2-negative early-stage breast cancer. Yet testing based on clinical and family-history criteria misses many carriers. BRCAura is designed as a pre-screening step that rules out patients unlikely to carry a mutation, so that genetic testing can be focused where it matters most.
Across all six validation cohorts, BRCAura maintained a sensitivity above 93% while ruling out around a third of patients. Aigora’s cohort comprised 230 preoperative biopsies with confirmed germline BRCA1/2 status. On this cohort, BRCAura achieved an AUROC of 0.82, consistent with the 0.81 observed across the five surgical resection cohorts.
Read the publication in npj Precision Oncology
About Aigora
Aigora is a real-world data partner for life sciences and medtech companies. Through its network of more than 300 healthcare partner sites across Europe and beyond, Aigora discovers, sources, curates and delivers multimodal, regulatory-grade datasets tailored to specific research and development needs.